Tychon Bioscience
Pre-clinicalDespite its promise as a new cancer treatment, clinical adoption of T-cell based immunotherapy has been slow due to a variety of shortcomings. Our therapy delivers on this promise by addressing these shortcomings with a novel approach.
Founded
2018
Focus
Viral Technology
About
Despite its promise as a new cancer treatment, clinical adoption of T-cell based immunotherapy has been slow due to a variety of shortcomings. Our therapy delivers on this promise by addressing these shortcomings with a novel approach.
Funding History
1Total raised: $3.5M
Seed$3.5MUndisclosedMar 15, 2022
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile